---
title: FDA-approved therapies for chronic GVHD
date: '2025-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39786434/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250110170836&v=2.18.0.post9+e462414
source: Blood
description: Despite novel prophylactic regimens, chronic graft-versus-host disease
  (cGVHD) remains a challenging complication after allogeneic hematopoietic cell transplantation.
  Chronic GVHD can affect multiple organs and reduces quality of life, and treatment
  can cause serious side effects. In the last ten years, the drugs ibrutinib, ruxolitinib,
  belumosudil and axatilimab were FDA-approved for cGVHD. Here we discuss which signaling
  pathways and cell types are targeted, the clinical studies that were ...
disable_comments: true
---
Despite novel prophylactic regimens, chronic graft-versus-host disease (cGVHD) remains a challenging complication after allogeneic hematopoietic cell transplantation. Chronic GVHD can affect multiple organs and reduces quality of life, and treatment can cause serious side effects. In the last ten years, the drugs ibrutinib, ruxolitinib, belumosudil and axatilimab were FDA-approved for cGVHD. Here we discuss which signaling pathways and cell types are targeted, the clinical studies that were ...